Compare KRKR & CPHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KRKR | CPHI |
|---|---|---|
| Founded | 2010 | N/A |
| Country | China | China |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.5M | 9.2M |
| IPO Year | 2019 | N/A |
| Metric | KRKR | CPHI |
|---|---|---|
| Price | $4.75 | $1.69 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 3.4K | ★ 11.7K |
| Earning Date | 09-26-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $30,966,526.00 | $4,052,266.00 |
| Revenue This Year | $182.55 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.76 | $1.20 |
| 52 Week High | $21.36 | $3.35 |
| Indicator | KRKR | CPHI |
|---|---|---|
| Relative Strength Index (RSI) | 40.73 | 53.42 |
| Support Level | $4.11 | $1.45 |
| Resistance Level | $4.85 | $1.88 |
| Average True Range (ATR) | 0.26 | 0.09 |
| MACD | 0.00 | 0.03 |
| Stochastic Oscillator | 43.87 | 58.14 |
36KR Holdings Inc is a holding company and conducts its business mainly through its subsidiaries, a VIE, and subsidiaries of the VIE. The Group is engaging in providing content and business services to new economy participants in the PRC. Its content production process includes content creation, content editing, screening and monitoring, and content distribution. The Group mainly generates revenues from providing online advertising services, enterprise value-added services, and subscription services. The Group's principal operations and geographic markets are substantially located in PRC.
China Pharma Holding Inc is a drug manufacturing company. It is mainly engaged in the development, manufacture, and marketing of pharmaceutical products for human use in connection with a variety of high-incidence and high-mortality diseases and medical conditions prevalent in the People's Republic of China. The company mainly manufactures pharmaceutical products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. The product line of the company includes cefaclor dispersible tablets, clarithromycin granules, roxithromycin dispersible tablets, andrographolide tablets, ozagrel sodium for injection, gastrodin injection and others.